Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry

International Journal of Hematology
Hiroshi KawabataJapanese National Research Group on Idiopathic Bone Marrow Failure Syndromes

Abstract

The Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes has been conducting prospective registration, central review, and follow-up study for patients with aplastic anemia and myelodysplastic syndrome (MDS) since 2006. Using this database, we retrospectively analyzed the prognosis of patients with MDS. As of May 2016, 351 cases were registered in this database, 186 of which were eligible for the present study. Kaplan-Meier analysis showed that overall survival (OS) curves of the five risk categories stipulated by the revised international prognostic scoring system (IPSS-R) were reasonably separated. 2-year OS rates for the very low-, low-, intermediate-, high-, and very high-risk categories were 95, 89, 79, 35, and 12%, respectively. In the same categories, incidence of leukemic transformation at 2 years was 0, 10, 8, 56, and 40%, respectively. Multivariate analysis revealed that male sex, low platelet counts, increased blast percentage (>2%), and high-risk karyotype abnormalities were independent risk factors for poor OS. Based on these data, we classified Japanese MDS patients who were classified as intermediate-risk in IPSS-R, into the lower risk MDS category, highlighting the need for careful assess...Continue Reading

References

Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie SchanzDetlef Haase
Jun 29, 2012·The American Journal of Medicine·Roger M Lyons
Dec 10, 2013·Hematology·Rafael Bejar
Jan 21, 2014·Leukemia Research·Jean E GoasguenUNKNOWN International Working Group on Morphology of MDS (IWGM-MDS)
Aug 5, 2014·Journal of Epidemiology·Dai ChiharaKeitaro Matsuo
Dec 3, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M F van SpronsenA A van de Loosdrecht

❮ Previous
Next ❯

Citations

Oct 26, 2018·International Journal of Hematology·Naoki ShingaiHironori Harada
Oct 27, 2018·Current Treatment Options in Oncology·Julia MontoroAzra Raza
Jul 31, 2019·International Journal of Hematology·Hiroshi KawabataUNKNOWN Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes
Feb 23, 2021·Frontiers in Oncology·Ming-Jing WangXiao-Mei Hu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.